IRONWOOD PHARMACEUTICALS Business Summary

Ironwood Pharmaceuticals Inc. (IRWD) is a commercial-stage biotechnology leader specializing in gastrointestinal (GI) and rare diseases, primarily generating revenue through its blockbuster product LINZESS (linaclotide). The company operates under a 50/50 U.S. profit-sharing collaboration with AbbVie and earns royalties from international partners including Astellas and AstraZeneca. As of early 2026, Ironwood has pivoted its business model toward 'net pricing optimization,' lowering the LINZESS list price to eliminate inflationary rebates and improve access within Medicaid and commercial channels. The company is also expanding its portfolio into the rare disease sector with apraglutide, a GLP-2 analog for Short Bowel Syndrome with Intestinal Failure (SBS-IF) slated for confirmatory Phase 3 trials in H1 2026. Ironwood maintains a dominant position in the IBS-C and CIC markets, competing directly with Ardelyx (Ibsrela), Bausch Health’s Salix division (Trulance), and AbbVie’s internal GI assets. Founded in 1998 by Peter Hecht, Brian Cali, and Todd Milne, Ironwood is currently led by CEO Thomas McCourt, a veteran commercial strategist who has been with the firm since 2009. The executive leadership team includes CFO Gregory Martini, Chief Commercial Officer Tammi Gaskins (promoted in January 2025), and Chief Medical Officer Michael Shetzline. The company’s strategic trajectory is significantly shaped by its Board of Directors, which includes Chair Julie McHugh and activist investor Alexander Denner of Sarissa Capital Management, a key institutional stakeholder. This leadership group has prioritized a 'discipline-first' operational approach, utilizing the robust cash flows from the LINZESS franchise to de-risk the rare disease pipeline acquired through the 2023 purchase of VectivBio.